FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1163-1165 October 15, 1998 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Related Article by The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators PubMed Citation

To the Editor: The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) and Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) studies (May 21 issue)^1,2 left me confused. The studies were conducted almost simultaneously, but they found different results with the use of tirofiban alone, which were not adequately explained by the editorialists.³ There was no effect of tirofiban alone in the PRISM-PLUS study (treatment in this group was in fact stopped early), whereas in the PRISM study tirofiban alone was suggested as a treatment option. Is there an explanation for these . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.